Swissmedic approves Beyfortus for RSV prophylaxis in newborns, infants and young children

Bern, 28.12.2023 - Following a thorough review, Swissmedic has authorised the medicinal product Beyfortus from marketing authorisation holder Sanofi-Aventis (Suisse) SA. Beyfortus is used for the prophylaxis of lower respiratory tract disease caused by the respiratory syncytial virus (RSV).

RSV is a respiratory tract virus that usually causes mild, cold-like symptoms. In newborns, infants and young children, however, the virus can trigger illness leading to pneumonia or bronchiolitis (inflammation of the small airways in the lungs). Beyfortus (with the monoclonal antibody nirsevimab) is administered intramuscularly as a single injection.

Address for enquiries

Media Unit

+41 58 462 02 76


Swiss Agency for Therapeutic Products